Skip to content
DataLookout
Menu

NCT07931365

Assessment of the Efficacy of E. Coli 5C in the Management of Post-Colonoscopy Symptoms

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in Gastrointestinal Symptom Rating Scale (GSRS) total score at Day 14
Timeframe: Baseline to Day 14 after colonoscopy

Secondary (11)

Change in abdominal pain intensity score
Change in abdominal bloating intensity score
Change in flatulence intensity score
Change in stool consistency assessed by Bristol Stool Form Scale
Change in frequency of bowel movements
Show 6 moreShow less
Global Assessment of Change of Gastrointestinal Symptoms (PGIC) score at Day 7 and Day 14
Proportion of participants with clinically relevant improvement in gastrointestinal symptoms
Use of rescue medication for gastrointestinal symptoms
Frequency of adverse events
Treatment tolerability score
Adherence to treatment

Arms and interventions

Escherichia coli 5C (Colipral®)Experimental

Participants in this arm will receive Colipral® (dietary supplement containing Escherichia coli 5C), administered twice daily, with 1 capsule in the morning and 1 capsule in the evening after dinner, for 14 days immediately following colonoscopy.

PlaceboPlacebo comparator

Participants in this arm will receive placebo, identical in appearance but not containing the probiotic strain, administered twice daily, with 1 capsule in the morning and 1 capsule in the evening after dinner, for 14 days immediately following colonoscopy.

Dietary supplements: Colipral®

Other: Placebo

Sites

1 site in 1 country

  • Clinica ARS Biomedica - Via Luigi Bodio 58Roma, Italy